Exeliom Biosciences raises €2.85M to advance Precision Cancer Immunotherapy
Clinical-stage biotech Exeliom Biosciences has secured an additional €2.85 million in Series A funding, bringing its total Series A round to €11.85 million.

The best Articles in our Network